Literature DB >> 15344186

Two-stage adaptive strategy for superiority and non-inferiority hypotheses in active controlled clinical trials.

Weichung J Shih1, Hui Quan, Gang Li.   

Abstract

In active controlled trials without a placebo arm, there are usually two study objectives: to test a superiority hypothesis that the experimental treatment is more effective than the active control therapy, and to test a non-inferiority hypothesis that the experimental treatment is therapeutically no worse than the active control within a defined margin. For a two-stage adaptive design, it is not necessary to give a fixed sample size calculation at the planning stage of the study when treatment effect information is often insufficient. Instead, decision and estimation of the design specifications can be made more reliably after the first stage when interim results are available. We propose the use of conditional power approach to determine the sample size and critical values for testing the superiority and non-inferiority hypotheses for the second stage based on the observed result of the first stage. The proposed adaptive procedure preserves the overall type I error rate for both superiority and non-inferiority, and has the flexibility of early termination of the study (for futility or efficacy) or extending the study by appropriate sample size. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2004        PMID: 15344186     DOI: 10.1002/sim.1877

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations.

Authors:  Aiyi Liu; Chunling Liu; Qizhai Li; Kai F Yu; Vivian W Yuan
Journal:  Clin Trials       Date:  2010-08-04       Impact factor: 2.486

2.  Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Authors:  Hartmut Döhner; Michael Lübbert; Walter Fiedler; Loic Fouillard; Alf Haaland; Joseph M Brandwein; Stephane Lepretre; Oumedaly Reman; Pascal Turlure; Oliver G Ottmann; Carsten Müller-Tidow; Alwin Krämer; Emmanuel Raffoux; Konstanze Döhner; Richard F Schlenk; Florian Voss; Tillmann Taube; Holger Fritsch; Johan Maertens
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.